clinical-decision-support

Clinical Decision Support Document Generation – Clinical Decision Support

Skills Overview

Generate professional clinical decision support documents for pharmaceutical companies and clinical researchers, including biomarker-stratified patient cohort analyses and GRADE-based treatment recommendation reports, delivered in publication-quality LaTeX/PDF format.

Use Cases

1. Drug Development and Clinical Trials

Used throughout the various stages of new drug development—including Phase 2/3 trial analyses, regulatory submissions, and companion diagnostic development—to generate biomarker-stratified efficacy and safety analysis reports that meet IND/NDA requirements and support regulatory review and drug commercialization decisions.

2. Clinical Guidelines and Evidence Synthesis

Provide evidence synthesis tools for clinical guideline committees of professional societies. Using the GRADE methodology to evaluate evidence from multiple clinical trials, generate practice guidelines containing treatment decision algorithms and evidence-based recommendations, suitable for publication as medical journal articles or official society documents.

3. Real-World Evidence Research

Analyze real-world patient cohort data from electronic medical records, conduct biomarker subgroup analyses, plot survival curves, calculate hazard ratios, and perform other statistical assessments to generate comparative effectiveness research reports suitable for medical affairs KOL education and medical strategy development.

Core Functions

1. Biomarker-Stratified Patient Cohort Analysis

Stratify patient populations by biomarkers—including gene mutations, copy-number variations, gene fusions, IHC markers, and PD-L1 scores—and compare efficacy endpoints such as ORR, PFS, OS, and DOR. Generate Kaplan–Meier survival curves, waterfall plots, forest plots, and other visualizations, with statistical analyses including hazard ratios, p-values, and 95% confidence intervals.

2. GRADE-Based Treatment Recommendation Reports

Based on systematic literature reviews and clinical trial data, use the GRADE system to rate the quality of evidence supporting treatment recommendations (1A, 1B, 2A, 2B, 2C). Generate evidence-based treatment guidelines containing recommendation strength, evidence-quality assessments, treatment algorithm flowcharts (TikZ), and biomarker-based decision criteria.

3. Publication-Quality Document Output

Generate LaTeX/PDF documents that meet pharmaceutical industry and clinical research standards, using compact 0.5-inch margins, color-coded recommendation boxes, professional statistical charts, HIPAA de-identification procedures, and regulatory compliance statements. Documents are suitable for regulatory submissions, peer-reviewed publication, and internal decision-making.

Frequently Asked Questions

What is the difference between clinical decision support and treatment plans?

Clinical decision support focuses on population-level analysis and evidence synthesis. Its target users are pharmaceutical companies, clinical researchers, and guideline committees. It produces 5–15-page, multi-page analytical reports containing extensive statistical charts and evidence ratings. Treatment plans focus on individual patients’ bedside care and are intended for clinicians and patient care teams, generating concise 1–4-page action plans. If your needs involve cohort analysis, biomarker stratification, or evidence-based guideline development, use this skill. If you need to develop a treatment regimen for an individual patient, use the treatment-plans skill.

What types of statistical analyses and biomarkers are supported?

This skill supports comprehensive survival analysis methods, including Kaplan–Meier curves, log-rank tests, and Cox regression; efficacy endpoint calculations, including ORR, DCR, median PFS/OS, and DOR; and subgroup comparisons involving hazard ratios, 95% CIs, and p-values. Biomarker coverage includes genomic alterations—such as point mutations, CNVs, and fusions—gene-expression signatures, immunohistochemical markers, PD-L1 scores, and disease-specific molecular subtypes, such as the mesenchymal–immune-active and proneural subtypes of GBM. All statistical methods comply with clinical research reporting standards.

Can the generated documents be used for regulatory submissions and peer-reviewed publication?

Yes. The documents use publication-quality LaTeX formatting and include compact 0.5-inch margins, professional statistical charts—such as survival curves with numbers-at-risk tables, waterfall plots, and forest plots—GRADE evidence-rating tables, and HIPAA de-identification procedures. They are fully compliant with IND/NDA regulatory submission requirements and CONSORT/STROBE reporting standards. The document structure includes an executive summary on the cover page, detailed methodology, results presentation, and a reference list, making the documents suitable for FDA/EMA submission materials, peer-reviewed journals, and clinical society guidelines.